<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039299</url>
  </required_header>
  <id_info>
    <org_study_id>XCYTE-SPR-080011</org_study_id>
    <secondary_id>UCLA-0111008</secondary_id>
    <secondary_id>CDR0000069370</secondary_id>
    <secondary_id>XCYTE-XT002</secondary_id>
    <secondary_id>NCI-G02-2075</secondary_id>
    <nct_id>NCT00039299</nct_id>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>A Phase I Safety Study Of Xcellerate In Patients With Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      tumor cells from growing. Treating a person's T cells in the laboratory and then reinfusing&#xD;
      them may cause a stronger immune response and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of T-cell therapy in treating patients who&#xD;
      have prostate cancer that has not responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety of activated autologous T cells (Xcellerate) therapy in patients&#xD;
           with hormone-refractory prostate cancer.&#xD;
&#xD;
        -  Determine the change in prostate-specific antigen (PSA) levels in patients treated with&#xD;
           this therapy.&#xD;
&#xD;
        -  Determine the effects on bone in patients treated with this therapy.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo leukapheresis to collect peripheral blood mononuclear cells (PBMC). PBMC are&#xD;
      activated and expanded ex vivo by costimulation with antihuman CD3 and antihuman CD28&#xD;
      monoclonal antibodies covalently attached to superparamagnetic microbeads (Xcellerate).&#xD;
      Xcellerate-activated T cells are reinfused on day 0.&#xD;
&#xD;
      Patients are followed weekly for 4 weeks and then monthly for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
               -  Evidence of androgen-independent disease&#xD;
&#xD;
                    -  Patient must have received prior primary hormonal therapy (e.g., orchiectomy&#xD;
                       or gonadotropin-releasing hormone analog with or without antiandrogen)&#xD;
&#xD;
                    -  Demonstrated disease progression by any 1 of the following:&#xD;
&#xD;
                         -  Elevated PSA level (at least 5 ng/mL) that has serially risen from&#xD;
                            baseline on 2 occasions at least 1 week apart&#xD;
&#xD;
                         -  At least 1 new osseous lesion on bone scan&#xD;
&#xD;
                         -  More than 25% increase in the sum of the products of the perpendicular&#xD;
                            diameters of all bidimensionally measurable sites of disease&#xD;
&#xD;
          -  No CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGPT no greater than 1.5 times ULN&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  No active or chronic hepatitis B or C&#xD;
&#xD;
          -  No other hepatic dysfunction that would preclude study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
          -  Calcium less than 11 mg/dL&#xD;
&#xD;
          -  No renal dysfunction that would preclude study&#xD;
&#xD;
          -  No symptomatic hypercalcemia&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No pulmonary disease requiring inhaled steroids or bronchodilators&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No history of HIV 1 or 2 or human T-cell lymphotrophic virus (HTLV) 1 or 2&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer&#xD;
&#xD;
          -  No history of autoimmune disease (e.g., rheumatoid arthritis or multiple sclerosis)&#xD;
&#xD;
          -  No other major organ system dysfunction&#xD;
&#xD;
          -  No gastrointestinal, neurologic, or psychiatric dysfunction that would preclude study&#xD;
&#xD;
          -  Human anti-mouse antibody negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent growth factors, interleukin, interferons, or cytokines&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy or other systemic chemotherapy agent for prostate or any other&#xD;
             cancer&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior aminoglutethimide allowed&#xD;
&#xD;
          -  At least 4 weeks since prior flutamide&#xD;
&#xD;
          -  At least 6 weeks since prior bicalutamide or nilutamide&#xD;
&#xD;
          -  Concurrent luteinizing hormone-releasing hormone agonists should be continued&#xD;
&#xD;
          -  No concurrent corticosteroids or dexamethasone&#xD;
&#xD;
          -  No concurrent anti-androgens (e.g., flutamide, bicalutamide, or nilutamide)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior local radiotherapy&#xD;
&#xD;
          -  No prior radiopharmaceutical therapy (e.g., strontium chloride Sr 89 or samarium Sm&#xD;
             153 lexidronam pentasodium)&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Prior ketoconazole or PC-SPES allowed&#xD;
&#xD;
          -  At least 1 week since prior antibiotic, antifungal, or antiviral agents&#xD;
&#xD;
          -  At least 4 weeks since other prior systemic therapy for prostate cancer (except&#xD;
             bisphosphonates or hormonal therapy)&#xD;
&#xD;
          -  At least 6 weeks since prior investigational drugs or devices&#xD;
&#xD;
          -  No other concurrent therapy for this disease&#xD;
&#xD;
          -  No concurrent participation in another clinical trial&#xD;
&#xD;
          -  No concurrent bisphosphonates unless initiated prior to study&#xD;
&#xD;
          -  No concurrent immunosuppressive drugs&#xD;
&#xD;
          -  No other concurrent experimental therapies&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allan Pantuck, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1738</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2003</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 2, 2013</last_update_submitted>
  <last_update_submitted_qc>April 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

